Literature DB >> 30937527

[Sjögren's syndrome].

Torsten Witte1.   

Abstract

The prevalence of primary Sjögren's syndrome (pSS) is between 1:100 and 1:1000 and it is therefore the most common connective tissue disease. Nevertheless, it can be difficult to diagnose pSS as the symptoms are frequently unspecific and diagnostic markers are lacking in many patients. In addition, only few controlled therapeutic studies of pSS have been carried out so that the optimal management is not yet clear. Meanwhile, outcome parameters to monitor clinical improvement have been developed and a large number of therapeutic studies are currently being performed. This review article summarizes the current diagnostic and treatment options for pSS.

Entities:  

Keywords:  Connective tissue diseases; Outcome; Review; SSA antibodies; Treatment

Mesh：

Year:  2019        PMID： 30937527     DOI： 10.1007/s00393-019-0625-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


  23 in total

1.  Prevalence of antibodies against alpha-fodrin in Sjögren's syndrome: comparison of 2 sets of classification criteria.

Authors:  Torsten Witte; Torsten Matthias; Martina Oppermann; Klaus Helmke; Hans H Peter; Reinhold E Schmidt; Moshe Tishler
Journal:  J Rheumatol       Date:  2003-10       Impact factor: 4.666

Review 2.  Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain.

Authors:  Steven E Carsons; Frederick B Vivino; Ann Parke; Nancy Carteron; Vidya Sankar; Richard Brasington; Michael T Brennan; William Ehlers; Robert Fox; Hal Scofield; Katherine M Hammitt; Julius Birnbaum; Stuart Kassan; Steven Mandel
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-03-03       Impact factor: 4.794

3.  American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.

Authors:  S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

4.  Labial salivary gland biopsy in Sjögren's disease.

Authors:  D M Chisholm; D K Mason
Journal:  J Clin Pathol       Date:  1968-09       Impact factor: 3.411

5.  Immunohistologic analysis of lymphoid infiltrates in primary Sjogren's syndrome using monoclonal antibodies.

Authors:  T C Adamson; R I Fox; D M Frisman; F V Howell
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

Review 6.  The risk of lymphoma development in autoimmune diseases: a meta-analysis.

Authors:  Elias Zintzaras; Michael Voulgarelis; Haralampos M Moutsopoulos
Journal:  Arch Intern Med       Date:  2005-11-14

7.  Risk factors for positive minor salivary gland biopsy findings in Sjögren's syndrome and dry mouth patients.

Authors:  Michael T Brennan; Vidya Sankar; Rose Anne Leakan; David Kleiner; Jane C Atkinson; William E Wilkinson; Bruce J Baum; Stanley R Pillemer
Journal:  Arthritis Rheum       Date:  2002-04-15

Review 8.  Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis.

Authors:  Baodong Qin; Jiaqi Wang; Zaixing Yang; Min Yang; Ning Ma; Fenglou Huang; Renqian Zhong
Journal:  Ann Rheum Dis       Date:  2014-06-17       Impact factor: 19.103

9.  The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome.

Authors:  C Vitali; H M Moutsopoulos; S Bombardieri
Journal:  Ann Rheum Dis       Date:  1994-10       Impact factor: 19.103

10.  Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome.

Authors:  C P Robinson; J Brayer; S Yamachika; T R Esch; A B Peck; C A Stewart; E Peen; R Jonsson; M G Humphreys-Beher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205
View more
  2 in total

Review 1.  Metformin as a Treatment Strategy for Sjögren's Syndrome.

Authors:  Joa Kim; Yun-Sung Kim; Sung-Hwan Park
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

2.  IRF9 and XAF1 as Diagnostic Markers of Primary Sjogren Syndrome.

Authors:  Lu Xiao; Zhou Yang; Shudian Lin
Journal:  Comput Math Methods Med       Date:  2022-09-12       Impact factor: 2.809
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.